Article
Epigenetic engineering for optimal chimeric antigen receptor T cell therapy
24 Aug 2022
Abstract excerpt
Recent advancements in cancer immunotherapy, such as chimeric antigen receptor (CAR)-engineered T cell therapy and immune checkpoint therapy, have significantly improved the clinical outcomes of patients with several types of cancer. To broaden its applicability further and induce durable therapeutic efficacy, it is imperative to understand how antitumor T cells elicit cytotoxic functions, survive as memory T...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
